FOURTH DEED OF TRUST NOTE MODIFICATION AGREEMENT

EXHIBIT 10.11

FOURTH DEED OF TRUST NOTE MODIFICATION AGREEMENT

THIS FOURTH DEED OF TRUST NOTE MODIFICATION AGREEMENT (this “Agreement”) is made this 1st day of October, 2001, by and among BIORELIANCE CORPORATION, a corporation organized and in good standing under the laws of the State of Delaware, successor in interest to Microbiological Associates, Inc. (the “Company”), BIORELIANCE TESTING AND DEVELOPMENT, LLC, a limited liability company organized and in good standing under the laws of the State of Delaware (“BT&D LLC”), BIORELIANCE MANUFACTURING, LLC, a limited liability company organized and in good standing under the laws of the State of Delaware (“BMF LLC”) and BIORELIANCE VIRAL MANUFACTURING, INC. (formerly known as Magenta Viral Production, Inc.), successor in interest to BioReliance Testing and Development, Inc. and BioReliance Manufacturing, Inc. a corporation organized and in good standing under the laws of the State of Delaware (“Viral Manufacturing;” together with the Company and BT&D LLC and BMF LLC, each a “Borrower” and collectively, the “Borrowers”) and BANK OF AMERICA, N.A., successor in interest to Nationsbank, N.A., each a national banking association, its successors and assigns, (the “Lender”).

INTRODUCTORY STATEMENT

A. The Lender has made a loan (the “Loan”) in the original principal amount of Three Million Dollars ($3,000,000) to the Company and Microbiological Associates International Limited, which changed its name to BioReliance Limited (“MAL”) pursuant to the terms of a Deed of Trust Note dated December 17, 1993 from the Borrower and MAL, which Deed of Trust Note was amended by that certain First Loan Modification Agreement (the “First Loan Modification Agreement”) dated May 31, 1994 by and among the Lender, the Company, MAL, Magenta and Magenta Services, which among other things added Magenta and Magenta Services as joint and several co-makers to the Deed of Trust Note, which Deed of Trust Note was further amended by that certain Second Loan Modification Agreement dated September 30, 1994 by and among the Company, MAL, Magenta, Magenta Services and the Lender, which Deed of Trust Note was amended and restated in its entirety pursuant to the provisions of that certain Third Loan Modification Agreement dated as of December 1, 1994, by and among the Company, MAL, Magenta, Magenta Services and the Lender, which among other things, increased the maximum principal amount of the Loan from Three Million Dollars ($3,000,000) to Four Million Three Hundred Thousand Dollars ($4,300,000) and which Deed of Trust Note was further modified pursuant to that certain Deed of Trust Note Modification Agreement dated as of October 31, 1997 by and among the Borrowers and the Lender (the Deed of Trust Note as amended and restated from time to time, is hereinafter called, the “Note”).

B. The Loan is currently governed by the provisions of that certain Amended and Restated Replacement Loan Agreement of even date herewith by and among the Borrowers and the Lender (as the same may be amended from time to time, the “Restated Loan Agreement”).

C. The Loan is secured by, among other things, the Company’s leasehold interest in the property described (the “Property”) in that certain Leasehold Deed of Trust and Security Agreement dated December 17, 1993 from the Company to the trustees named therein for the benefit of the Lender, which Leasehold Deed of Trust and Security Agreement was recorded December 20, 1993, among the Land Records for ▇▇▇▇▇▇▇▇▇▇ County, Maryland in Liber 12140, at folio 779, and which Leasehold Deed of Trust and Security Agreement was amended by that certain Modification Agreement-Leasehold Deed of Trust and Security Agreement dated December 1, 1994 by and among the Company, the trustees named therein and the Lender (the Leasehold Deed of Trust and Security Agreement as amended is hereinafter called the “Deed of Trust”).

D. BioReliance Testing and Development, Inc., formerly known as MA BioServices, Inc. (“BT&D, Inc.”) and BioReliance Manufacturing, Inc, formerly known as Magenta Corporation (“BMF, Inc.”), were previously each a Borrower. Pursuant to a plan of reorganization effected on October 1, 2001 (the “Reorganization”), (i) BT&D, Inc. merged with and into BMF, Inc. and BT&D, Inc. ceased to exist; (ii) BMF, Inc. formed BT&D LLC and contributed all of BT&D, Inc.’s assets (except for certain real property and leasehold improvements) and liabilities to BT&D LLC; (iii) BMF, Inc. merged with and into Magenta Viral Production, Inc. (“Magenta Viral”) and BMF, Inc. ceased to exist; (iv) Magenta Viral formed BMF LLC and contributed substantially all of BMF, Inc.’s assets and liabilities to BMF LLC; and (v) Magenta Viral changed its name to BioReliance Viral Manufacturing, Inc.

E. As a result of the Reorganization, the Borrowers have requested and the Lender has agreed to add BT&D LLC and BMF LLC as joint and several co-makers of the Deed of Trust Note.

F. On this date the Company continues to be the leasehold owner of the Property and the Borrowers acknowledge and agree that the Deed of Trust constitutes a valid and subsisting first lien on the Company’s leasehold interest in the Property for the entire outstanding principal balance of the Note and interest thereon, all in accordance with the terms, covenants, conditions and warranties of the Deed of Trust and the Note secured thereby, and that all of the other provisions of the same are in full force and effect.

G. In order to induce the Lender to enter this Agreement and upon the express condition that the lien of the Deed of Trust remains a valid and subsisting first lien on the Company’s leasehold interest in the Property and that the execution and delivery of this Agreement shall not impair the lien thereof, the parties hereto have agreed to execute and deliver this Agreement to modify the terms of repayment of the Loan as hereinafter more particularly set forth.

AGREEMENTS

NOW, THEREFORE, in consideration of the premises and for the sum of One Dollar ($1.00) and other good and valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, the parties hereto, for themselves, their respective heirs, personal representatives, successors and assigns do hereby mutually covenant and agree as follows:

1. Incorporation of Recitals. The parties hereto acknowledge and agree that the recitals hereinabove set forth are true and correct in all respects and that the same are incorporated herein and made a part hereof.

2. Outstanding Obligations. The parties hereto acknowledge and agree (a) that the outstanding principal balance of the Note as of the date hereof is $2,305,526.59 (the “Principal Sum”), (b) that interest on the unpaid principal balance of the Note has been paid through October 1, 2001, and (c) that the unpaid principal balance of the Note, together with accrued and unpaid interest thereon, is due and owing subject to the terms of repayment hereinafter set forth, without defense or offset.

3. Confirmation of Lien. The Borrowers hereby acknowledge and agree that the Property is and shall remain in all respects subject to the lien, charge and encumbrance of the Deed of Trust, and nothing herein contained, and nothing done pursuant hereto, shall adversely affect or be construed to adversely affect the lien, charge or encumbrance of, or warranty of title in, or conveyance effected by the Deed of Trust, or the priority thereof over other liens, charges, encumbrances or conveyances, or to release or adversely affect the liability of any party or parties whomsoever who may now or hereafter be liable under or on account of the Loan or any of the Loan Documents (as hereinafter defined), nor shall anything herein contained or done in pursuance hereof adversely affect or be construed to adversely affect any other security or instrument held by the Lender as security for or evidence of the indebtedness evidenced and secured thereby.

4. Continuation of Loan Terms. Except as otherwise expressly set forth below, the outstanding principal balance of the Note shall continue to bear interest and to be repaid on the terms and subject to the conditions set forth in the Note and the other documents evidencing and securing the Loan (this Agreement, the Note, the Deed of Trust, the Restated Loan Agreement and all such other documents, whether currently existing or hereafter executed, and all modifications thereto, extensions or renewals thereof and substitutions therefor being hereinafter collectively referred to as the “Loan Documents”). All capitalized terms used but not defined in this Agreement shall have the meaning given to such terms in the Loan Documents.

5. Interest. Commencing as of the 1st day of February, 2002, until all sums due under the Loan shall be repaid in full, the unpaid principal balance of the Note shall bear interest

at a rate which is at all times equal to the fluctuating at the LIBOR Rate (as hereinafter defined), plus the applicable LIBOR Rate Additional Percentage (the “LIBOR Rate Option”).

(a) For purposes hereof, the “LIBOR Rate Additional Percentage” shall mean the percentages applicable to the Loan in accordance with the following:


	(i) If the ratio of Funded Debt divided by EBITDA is equal to or greater than 2.75 to 1.0, the LIBOR Rate Additional Percentage shall be two and 15/100 percent (2.15%);


	(ii) If the ratio of Funded Debt divided by EBITDA is less than 2.75 to 1.0, but equal to or greater than 2.0 to 1.0, the LIBOR Rate Additional Percentage shall be one and nine tenths percent (1.90%);


	(iii) If the ratio of Funded Debt divided by EBITDA is less than 2.0 to 1.0, but equal to or greater than 1.25 to 1.0 the LIBOR Rate Additional Percentage shall be one and four tenths percent (1.40%); and


	(iv) If the ratio of Funded Debt divided by EBITDA is less than 1.25 to 1.0, the LIBOR Rate Additional Percentage shall be one percent (1.0%).

(b) The initial the LIBOR Rate Additional Percentage shall be two and 15/100 percent (2.15%). Thereafter, the applicable LIBOR Rate Additional Percentage for all Advances shall be calculated and adjusted quarterly, based on the quarterly financial statements of the Borrowers required to be submitted to the Lender pursuant to Section 5.1(c) of the Restated Loan Agreement, commencing with the statements for the quarter ending September 30, 2001. Such quarterly changes shall be effective commencing five (5) Banking Days after submission by the Borrowers of the required financial statements; it being understood, however, that in the event the quarterly financial statements are not submitted when due, the LIBOR Rate Additional Percentage shall be two and 15/100 percent (2.15%), until such financial statements are submitted as required, at which time, the LIBOR Rate Additional Percentage (for the balance of the quarterly period) shall be determined as set forth above. For purposes of the Note, “Funded Debt” and “EBITDA” shall each be determined based on the consolidated quarterly financial statements of the Borrowers and shall have the meanings set forth in the Restated Loan Agreement.

(c) For purposes hereof, the “LIBOR Rate” shall mean a fluctuating rate equal to the daily London Interbank Offered Rate for thirty (30) day U.S. Dollar deposits as quoted by the Lender as of 11:00 A.M. (Washington, D.C. time), which rate shall be adjusted for any Federal Reserve Board reserve requirements imposed upon the Lender from time to time.

(d) The Borrowers shall pay to the Lender, as additional interest, the following sums, at the time and in the manner hereinafter set forth:

(i) if, due to either: (i) the introduction of or any change (including, without limitation, any change by way of imposition or increase of reserve requirements) in or in the interpretation of any law or regulation or (ii) the compliance by the Lender with any guideline or request from any central bank or other governmental authority (whether or not having the force of law), there shall be any increase in the cost to the Lender of agreeing to make or making, funding or maintaining advances of all or a portion of the Principal Sum, then the Borrowers shall from time to time, upon demand by the Lender, pay to the Lender additional amounts to indemnify the Lender against any such increased costs. A certificate as to the amount of such increased costs submitted to the Borrowers by the Lender shall be conclusive. It shall be deemed, for purposes of computing any increased costs pursuant to this Section, that (i) the making and maintaining of advances of the Principal Sum which accrue interest based on the LIBOR Rate have been made by the Lender from its office in London, England and (ii) the funding of each Advance of the Principal Sum by the Lender which accrues interest based on the LIBOR Rate has been made through the London Interbank Market. Such additional cost shall be payable hereunder at the time and in the manner that interest is payable hereunder for such costs incurred since the last interest payment;

(ii) the Borrowers shall also pay to the Lender at the time and in the manner that interest is payable hereunder for each advance, the cost since the last interest payment date, as determined in good faith by the Lender, of complying, in connection with such advance during such interest period, with any reserve, special deposit or similar requirement (including but not limited to reserve requirements under Federal Reserve Regulation D) imposed or deemed applicable against any assets held by or deposits or accounts in or with or credit extended by the Lender, or the office of the Lender in London, England, by any United States governmental authority charged with the administration of such requirements. Each notification as to the amount of such cost, delivered to the Borrowers by the Lender shall, in the absence of manifest error, be conclusive as to the amount of such cost. It shall be deemed for purposes of computing cost pursuant to the above provision that the making and maintaining of each advance which accrues interest based on the LIBOR Rate has been made by the Lender through its office in London, England.

(e) In respect to any interest rate election hereunder and any transactions contemplated hereby, the Borrowers authorize the Lender to accept, rely upon, act upon and comply with, any verbal or written instructions, requests, confirmations and orders of Capers ▇. ▇▇▇▇▇▇▇▇, President and CEO or ▇▇▇▇ ▇. ▇▇▇▇▇, CFO, or their successors in office or on behalf of the Borrowers. The Borrowers acknowledge and agree that the transmission between the Borrowers and the Lender of any such instructions, requests, confirmations and orders involves the possibility of errors, omissions, mistakes and discrepancies and agrees to adopt such internal measures and operational procedures to protect its interests. By reason thereof, the Borrowers hereby assume all risk of loss and responsibility for, releases and discharges the Lender from any and all responsibility or liability for, and agrees to indemnify, reimburse on demand and hold the Lender harmless from, any and all claims, actions, damages, losses, liability and expenses by reason of, arising out of or in any way connected with or related to, (i) the Lender’s acceptance,

reliance and actions upon, compliance with or observation of any such instructions, requests, confirmations or orders, and (ii) any such errors, omissions, mistakes and discrepancies, except those caused by the Lender’s gross negligence or willful misconduct.

(f) All interest payable under the terms of the Note shall be calculated on the basis of a 360-day year and the actual number of days elapsed.

6. Payments and Maturity. The unpaid principal balance of the Note, together with interest thereon at the rate or rates provided above, shall be payable as follows:

(a) Commencing on the 1st day of November, 2001 and continuing on the same day of each and every month thereafter, to and including November 1, 2009, principal shall be due and payable in equal installments of $10,575.81, plus all accrued and unpaid interest on the outstanding balance of the Principal Sum; and

(b) Unless sooner paid, the unpaid principal balance of the Loan, together with interest accrued and unpaid thereon, shall be due and payable in full on November 1, 2009.

7. Additional Parties; Assumption. BT&D LLC and BMF LLC agree (i) to become joint and several co-makers of the Note; (ii) to be bound by all the terms and conditions of the Note; (iii) to assume and agree to pay and perform when due all present and future indebtedness, liabilities and obligations of a Borrower under, based upon, or arising out of the Loan Documents and instruments and agreements relating thereto; and (iv) to honor, perform and comply with, in all respects, all terms and provisions of all of the Loan Documents. All references in the Loan Documents to “Borrower” shall be deemed to refer to BT&D LLC and BMF LLC. Furthermore, all present and future obligations of the Borrowers under the Loan Documents shall be deemed to refer to all present and future obligations of BT&D LLC and BMF LLC.

8. Releases. The Lender, for itself, its successors and assigns hereby releases each of each of the Released Parties from any and all liability on account of the Loan, the Note and the Loan Documents. This release shall be binding upon the Lender and its successors and assigns and shall inure to the benefit of the Released Parties and their respective present and former employees, agents, successors and assigns.

9. ARBITRATION. ANY CONTROVERSY OR CLAIM BETWEEN OR AMONG THE PARTIES HERETO INCLUDING BUT NOT LIMITED TO THOSE ARISING OUT OF THIS AGREEMENT, THE LOAN DOCUMENTS, OR ANY RELATED INSTRUMENTS, AGREEMENTS OR DOCUMENTS, INCLUDING ANY CLAIM BASED ON OR ARISING FROM AN ALLEGED TORT, SHALL BE DETERMINED BY BINDING ARBITRATION IN ACCORDANCE WITH THE FEDERAL ARBITRATION ACT (OR IF NOT APPLICABLE, THE APPLICABLE STATE LAW), THE RULES OF PRACTICE AND PROCEDURE FOR ARBITRATION OF COMMERCIAL DISPUTES OF ENDISPUTE, INC., D/B/A J.A.M.S./ENDISPUTE (“J.A.M.S.”) AND THE “SPECIAL RULES” SET FORTH BELOW. IN THE EVENT OF AN INCONSISTENCY, THE SPECIAL RULES SHALL

CONTROL. JUDGMENT UPON ANY ARBITRATION AWARD MAY BE ENTERED IN ANY COURT HAVING JURISDICTION. ANY PARTY TO THIS INSTRUMENT, AGREEMENT OR DOCUMENT MAY BRING ANY ACTION, INCLUDING A SUMMARY OR EXPEDITED PROCEEDING, TO COMPEL ARBITRATION OF ANY CONTROVERSY OR CLAIM TO WHICH THIS INSTRUMENT, AGREEMENT OR DOCUMENT RELATES IN ANY COURT HAVING JURISDICTION OVER SUCH ACTION.

(A) SPECIAL RULES. THE ARBITRATION SHALL BE CONDUCTED IN ▇▇▇▇▇▇▇▇▇▇ COUNTY, MARYLAND AND ADMINISTERED BY J.A.M.S. WHO WILL APPOINT AN ARBITRATOR. IF J.A.M.S. IS UNABLE OR LEGALLY PRECLUDED FROM ADMINISTERING THE ARBITRATION, THEN THE AMERICAN ARBITRATION ASSOCIATION WILL SERVE. ALL ARBITRATION HEARINGS WILL BE COMMENCED WITHIN NINETY (90) DAYS OF THE DEMAND FOR ARBITRATION; FURTHER, THE ARBITRATOR SHALL ONLY, UPON A SHOWING OF CAUSE, BE PERMITTED TO EXTEND THE COMMENCING OF SUCH HEARING FOR AN ADDITIONAL SIXTY (60) DAYS.

(B) RESERVATION OF RIGHTS. NOTHING IN THIS INSTRUMENT, AGREEMENT OR DOCUMENT SHALL BE DEEMED TO: (I) LIMIT THE APPLICABILITY OF ANY OTHERWISE APPLICABLE STATUTES OF LIMITATION OR REPOSE AND ANY WAIVERS CONTAINED IN THIS INSTRUMENT, AGREEMENT OR DOCUMENT; OR (II) BE A WAIVER BY THE LENDER OF THE PROTECTION AFFORDED TO IT BY 12 ▇.▇.▇. §▇▇ OR ANY SUBSTANTIALLY EQUIVALENT STATE LAW; OR (III) LIMIT THE RIGHT OF THE LENDER: (A) TO EXERCISE SELF HELP REMEDIES SUCH AS (BUT NOT LIMITED TO) SETOFF, OR (B) TO FORECLOSE AGAINST ANY REAL OR PERSONAL PROPERTY COLLATERAL, OR (C) TO OBTAIN FROM A COURT PROVISIONAL OR ANCILLARY REMEDIES SUCH AS (BUT NOT LIMITED TO) INJUNCTIVE RELIEF, WRIT OF POSSESSION OR THE APPOINTMENT OF A RECEIVER. THE LENDER MAY EXERCISE SUCH SELF HELP RIGHTS, FORECLOSE UPON SUCH PROPERTY, OR OBTAIN SUCH PROVISIONAL OR ANCILLARY REMEDIES BEFORE, DURING OR AFTER THE PENDENCY OF ANY ARBITRATION PROCEEDING BROUGHT PURSUANT TO THIS INSTRUMENT, AGREEMENT OR DOCUMENT. NEITHER THE EXERCISE OF SELF HELP REMEDIES NOR THE INSTITUTION OR MAINTENANCE OF ANY ACTION FOR FORECLOSURE OR FOR PROVISIONAL OR ANCILLARY REMEDIES SHALL CONSTITUTE A WAIVER OF THE RIGHT OF ANY PARTY, INCLUDING THE CLAIMANT IN SUCH ACTION, TO ARBITRATE THE MERITS OF THE CONTROVERSY OR CLAIM OCCASIONING RESORT TO SUCH REMEDIES.

10. Expenses. In consideration of the Lender’s agreement to modify the Loan, the Borrowers covenant and agree to pay all other reasonable fees, costs, charges and expenses incurred by the Lender in connection with the preparation of this Agreement and the modification of the Loan, including without limitation, the Lender’s reasonable attorneys fees and all recording costs.

11. Events of Default. The events of default specifically enumerated in the Note are hereby amended and replaced with the following enumerated events of default, and the occurrence of any of the following events shall constitute an event of default and shall entitle the Lender to exercise all rights and remedies provided in the Note and the Deed of Trust, as well as all other rights and remedies provided to the Lender under the terms of any of the other Loan Documents as a result of the occurrence of the same:

(a) The Borrowers shall fail to make any payment of principal or interest when due on the Note, or on any other promissory note or other obligation payable by any of the Borrowers to the Lender and such failure remains uncured for five (5) days after notice thereof;

(b) The Borrowers shall fail to comply with the terms of any covenant or agreement contained herein and such failure remains uncured for thirty (30) days after notice thereof; or

(c) An event of default (as described or defined therein) shall occur under any of the Loan Documents, and such event of default is not cured within any applicable grace period provided therein.

12. Release of Claims. The Borrowers for themselves and for each of their respective successors and assigns, hereby release and waive any and all claims and/or defenses they now may have against the Lender and its successors and assigns on account of any occurrence relating to the Loan, the Loan Documents and/or the Property which accrued prior to the date hereof, including, but not limited to, any claim that the Lender (a) breached any obligation to the Borrowers in connection with the Loan, (b) was or is in any way involved with the Borrowers as a partner, joint venturer, or in any other capacity whatsoever other than as a lender, (c) failed to fund any portion of the Loan or any other sums as required under any document or agreement in reference thereto, or (d) failed to timely respond to any offers to cure any defaults under any document or agreement executed by the Borrowers, or any third party or parties in favor of the Lender. This release and waiver shall be effective as of the date of this Agreement and shall be binding upon the Borrowers and each of their respective successors and assigns, and shall inure to the benefit of the Lender and its successors and assigns. The term “Lender” as used herein shall include, but shall not be limited to, its present and former officers, directors, employees, agents and attorneys.

13. Continuing Agreements; Novation. Except as expressly modified hereby, the parties hereto ratify and confirm each and every provision of the Note, the Deed of Trust and each of the other Loan Documents as if the same were set forth herein. In the event that any of the terms and conditions in the Note or in any of the other Loan Documents conflict in any way with the terms and provisions hereof, the terms and provisions of the Restated Loan Agreement shall prevail. The parties hereto covenant and agree that the execution of this Agreement is not intended to and shall not cause or result in a novation with regard to the Note, the Deed of Trust and/or the other Loan Documents and that the existing indebtedness of the Borrowers to the

Lender evidenced by the Note is continuing, without interruption, and has not been discharged by a new agreement.

14. ENTIRE AGREEMENT. NO STATEMENTS, AGREEMENTS OR REPRESENTATIONS, ORAL OR WRITTEN, WHICH MAY HAVE BEEN MADE TO ANY OF THE BORROWERS OR TO ANY EMPLOYEE OR AGENT OF ANY OF THE BORROWERS, EITHER BY THE LENDER OR BY ANY EMPLOYEE, AGENT OR BROKER ACTING ON THE LENDER’S BEHALF, WITH RESPECT TO THE MODIFICATION OF THE LOAN, SHALL BE OF ANY FORCE OR EFFECT, EXCEPT TO THE EXTENT STATED IN THIS AGREEMENT, AND ALL PRIOR AGREEMENTS AND REPRESENTATIONS WITH RESPECT TO THE MODIFICATION OF THE LOAN ARE MERGED HEREIN.

15. Captions. The captions herein set forth are for convenience only and shall not be deemed to define, limit or describe the scope or intent of this Agreement.

16. Governing Law. The provisions of this Agreement shall be construed, interpreted and enforced in accordance with the laws of the State of Maryland as the same may be in effect from time to time.

17. Counterparts. This Agreement may be executed in any number of counterparts, and each such counterpart shall be deemed to be an original. It shall not be necessary that the signature of, or on behalf of, each party, or that the signatures of the persons required to bind any party, appear on more than one counterpart.

[SIGNATURES BEGIN ON THE FOLLOWING PAGE]

IN WITNESS WHEREOF, the parties have executed this Agreement under seal as of the date first above written.


WITNESS/ATTEST:		BIORELIANCE CORPORATION

/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇		By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇ (SEAL) Name: ▇▇▇▇ ▇. ▇▇▇▇▇ Title: Vice President— Finance and Administration, Chief Financial Officer

WITNESS/ATTEST:		BIORELIANCE TESTING AND DEVELOPMENT, LLC

/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇		By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇ (SEAL) Name: ▇▇▇▇ ▇. ▇▇▇▇▇ Title: Vice President— Finance and Administration, Chief Financial Officer

WITNESS/ATTEST:		BIORELIANCE MANUFACTURING, LLC

/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇		By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇ (SEAL) Name: ▇▇▇▇ ▇. ▇▇▇▇▇ Title: Vice President— Finance and Administration, Chief Financial Officer

WITNESS/ATTEST:		BIORELIANCE VIRAL MANUFACTURING, INC.

/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇		By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇ (SEAL) Name: ▇▇▇▇ ▇. ▇▇▇▇▇ Title: Vice President— Finance and Administration, Chief Financial Officer



WITNESS:		BANK OF AMERICA, N.A.

/s/ ▇▇▇▇▇▇ ▇▇▇▇▇		By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ (SEAL) Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
		Title: Vice President

FOURTH DEED OF TRUST NOTE MODIFICATION AGREEMENT

Document Metadata

Document Metadata

Table of Contents